All lobbying filings

TIBER CREEK GROUP

Lobbying for DAIICHI SANKYO, INC. · Global pharmaceutical company.

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2025 · New Jersey · House · Senate · $50,000.00 income · posted Jul 20, 2025

Official filing document

Bills named in this filing 2

HR 946
ORPHAN Cures Act
S 1862
ORPHAN Cures Act

Lobbying activity 1

Health Issues

Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); Issues related to the 340b program - Public Health Service Act (PL 78-410); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to H.R. 946/S.1862 - ORPHAN Cures Act; Issues related to the One Big Beautiful Bill Act (PL 119-21).

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.